RADOCHA, J., Roman HÁJEK, Lucie BROŽOVÁ, Luděk POUR, I. ŠPIČKA, J. MINAŘÍK, E. GREGORA, A. JUNGOVÁ, T. JELÍNEK, A. HEINDORFER, M. SÝKORA and V. MAISNAR. Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis. Annals of hematology. New York: Springer Verlag, 2019, vol. 98, No 4, p. 951-962. ISSN 0939-5555. Available from: https://dx.doi.org/10.1007/s00277-018-3568-2.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Simplified novel prognostic score for real-life older adults with multiple myelomaregistry-based analysis
Authors RADOCHA, J. (203 Czech Republic, guarantor), Roman HÁJEK (203 Czech Republic), Lucie BROŽOVÁ (203 Czech Republic, belonging to the institution), Luděk POUR (203 Czech Republic, belonging to the institution), I. ŠPIČKA (203 Czech Republic), J. MINAŘÍK (203 Czech Republic), E. GREGORA (203 Czech Republic), A. JUNGOVÁ (203 Czech Republic), T. JELÍNEK (203 Czech Republic), A. HEINDORFER (203 Czech Republic), M. SÝKORA (203 Czech Republic) and V. MAISNAR (203 Czech Republic).
Edition Annals of hematology, New York, Springer Verlag, 2019, 0939-5555.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30205 Hematology
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 2.904
RIV identification code RIV/00216224:14110/19:00109477
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1007/s00277-018-3568-2
UT WoS 000461545800016
Keywords in English Multiple myeloma; Older adults; Prognostic factors
Tags 14110212, 14119612, rivok
Tags International impact, Reviewed
Changed by Changed by: Soňa Böhmová, učo 232884. Changed: 17/4/2019 13:00.
Abstract
The main goal was to find a simple prognostic to evaluate overall survival of patients older than 65years of age with myeloma. Retrospective registry-based analysis from the Registry of Monoclonal Gammopathies was conducted. Patients over 65years with symptomatic myeloma were included. The four major parameters with impact on survival were identified: male gender, age>75, creatinine >152mol/L, and ECOG performance status 2-4. The patients were scored as good (0 points), intermediate good (1 point), intermediate poor (2 points), poor (3-4 points). Patients (1410 MM) were included. Median OS (months) was 65.7 (95% CI 49.8-81.7) for good, 51.0 (44.1-57.8) for intermediate good, 32.2 (26.2-38.2) for intermediate poor, and 18.9 (15.1-22.7) for poor. The differences in OS were statistically significant (p<0.0001). Good score was used as reference for hazard ratios, which for each other score were 1.43 (1.09-1.84) for intermediate good, 2.58 (2.00-3.33) for intermediate poor, and 3.88 (2.94-5.10) for poor. Time to progression showed medians (months) 20.5 (17.4-62.4) for good, 19.3 (17.0-21.7) for intermediate good, 19.6 (16.2-23.0) for intermediate poor, and 13.0 (10.8-15.2) for poor. The suggested scoring system provides readily available information about the prognosis of MM patients above 65years.
PrintDisplayed: 21/7/2024 03:47